These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8850382)

  • 1. "Essential" phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease.
    Klimov AN; Konstantinov VO; Lipovetsky BM; Kuznetsov AS; Lozovsky VT; Trufanov VF; Plavinsky SL; Gundermann KJ; Schumacher R
    Cardiovasc Drugs Ther; 1995 Dec; 9(6):779-84. PubMed ID: 8850382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.
    Davignon J; Roederer G; Montigny M; Hayden MR; Tan MH; Connelly PW; Hegele R; McPherson R; Lupien PJ; Gagné C
    Am J Cardiol; 1994 Feb; 73(5):339-45. PubMed ID: 8109547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin.
    Hoeg JM; Maher MB; Bou E; Zech LA; Bailey KR; Gregg RE; Sprecher DL; Susser JK; Pikus AM; Brewer HB
    Circulation; 1984 Dec; 70(6):1004-11. PubMed ID: 6388897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease.
    Santanu G; Suhrita P; Mookerjee S; Tania K; Mita S; Pramit G; Sharmila G; Miraj M; Debdutta M
    Indian Heart J; 2011; 63(5):434-7. PubMed ID: 23550422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued benefit of lovastatin in the treatment of hypercholesterolemia in 36 patients.
    Wallace MB; Warren SG; Bates MC; Robinson PA
    W V Med J; 1995 Feb; 91(2):50-3. PubMed ID: 7610642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100.
    Schmidt EB; Illingworth DR; Bacon S; Russell SJ; Thatcher SR; Mahley RW; Weisgraber KH
    Metabolism; 1993 Feb; 42(2):137-9. PubMed ID: 8474308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypolipidemic effects of alisat and lipostabil in patients with diabetes mellitus].
    Mel'chinskaia EN; Gromnatskiĭ NI; Kirichenko LL
    Ter Arkh; 2000; 72(8):57-8. PubMed ID: 11019431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
    Virgolini I; Koller E; Li S; Yang Q; Banyai M; Rauscha F; Pidlich J; Pirker W; Sinzinger H
    Atherosclerosis; 1993 Sep; 102(2):217-26. PubMed ID: 8251008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prolonged treatment with slow release nicotinic acid in patients with type II hyperlipidemia].
    Chojnowska-Jezierska J; Adamska-Dyniewska H
    Pol Arch Med Wewn; 1997 Nov; 98(11):391-9. PubMed ID: 9594556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial.
    Harris WS; Dujovne CA; Zucker M; Johnson B
    Ann Intern Med; 1988 Sep; 109(6):465-70. PubMed ID: 3166357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinic acid for the treatment of hyperlipoproteinemia.
    Drood JM; Zimetbaum PJ; Frishman WH
    J Clin Pharmacol; 1991 Jul; 31(7):641-50. PubMed ID: 1894760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
    Simons LA; Hickie JB; Balasubramaniam S
    Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
    Hoeg JM; Maher MB; Bailey KR; Zech LA; Gregg RE; Sprecher DL; Brewer HB
    Am J Cardiol; 1985 May; 55(11):1282-6. PubMed ID: 3887883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.